| Entry |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Linezolid (JAN/USAN/INN); Zyvox (TN) | ||||||||||||
| Abbr | LZD | ||||||||||||
| Product | ZYVOX (Fresenius Kabi Norge As), ZYVOX (Fresenius Kabi Norge As), ZYVOX (Fresenius Kabi Norge As), LINEZOLID (Hospira), ZYVOX (Pharmacia & Upjohn Company LLC), ZYVOX (Pharmacia & Upjohn Company LLC), ZYVOX (Pharmacia & Upjohn Company LLC), ZYVOX (REMEDYREPACK) | ||||||||||||
| Generic | LINEZOLID (Alembic Pharmaceuticals), LINEZOLID (Alembic Pharmaceuticals Limited), LINEZOLID (American Health Packaging), LINEZOLID (Amneal Pharmaceuticals LLC), LINEZOLID (Ascend Laboratories), LINEZOLID (AuroMedics Pharma LLC), LINEZOLID (Bryant Ranch Prepack), LINEZOLID (CELLTRION USA), LINEZOLID (Cadila Healthcare Limited), LINEZOLID (Camber Pharmaceuticals), LINEZOLID (Fresenius Kabi Norge AS), LINEZOLID (Fresenius Kabi USA), LINEZOLID (Greenstone LLC), LINEZOLID (Greenstone LLC), LINEZOLID (Hikma Pharmaceuticals USA), LINEZOLID (Major Pharmaceuticals), LINEZOLID (Mylan Institutional LLC), LINEZOLID (Novel Laboratories), LINEZOLID (Piramal Critical Care), LINEZOLID (Piramal Critical Care), LINEZOLID (Sagent Pharmaceuticals), LINEZOLID (Sandoz), LINEZOLID (Sun Pharmaceutical Industries), LINEZOLID (Zydus Pharmaceuticals (USA)) | ||||||||||||
| Formula | C16H20FN3O4 | ||||||||||||
| Exact mass | 337.1438 | ||||||||||||
| Mol weight | 337.3461 | ||||||||||||
| Structure |  | ||||||||||||
| Simcomp | |||||||||||||
| Class | Antibacterial DG01789 Oxazolidinone antibiotic | ||||||||||||
| Remark |
| ||||||||||||
| Efficacy | Antibacterial, Protein biosynthesis inhibitor | ||||||||||||
| Disease | Vancomycin-Resistant Enterococcus faecium infection [DS:H00340] | ||||||||||||
| Target | 50S ribosomal subunit | ||||||||||||
| Interaction | |||||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J01 ANTIBACTERIALS FOR SYSTEMIC USE J01X OTHER ANTIBACTERIALS J01XX Other antibacterials J01XX08 Linezolid D00947 Linezolid (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Antibacterials Antibacterials, Other Linezolid D00947 Linezolid (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 624 Synthetic antibacterials 6249 Others D00947 Linezolid (JAN/USAN/INN) Drug groups [BR:br08330] Antibacterial DG01789 Oxazolidinone antibiotic D00947 Linezolid Antimicrobials [BR:br08307] Antibacterials Protein biosynthesis inhibitor Oxazolidinone D00947 Linezolid (JAN/USAN/INN) <JP/US> Antimicrobials abbreviations [BR:br08327] Antibacterials Protein biosynthesis inhibitor Oxazolidinone D00947 Linezolid (JAN/USAN/INN) New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D00947 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D00947 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D00947 | ||||||||||||
| Other DBs |
| ||||||||||||
| KCF data | ATOM 24 1 C8x C 18.4100 -19.7400 2 C8y C 18.4100 -18.3400 3 C8y C 17.1500 -17.6400 4 C8x C 15.9600 -18.3400 5 C8y C 15.9600 -19.7400 6 C8x C 17.1500 -20.4400 7 N1y N 19.6000 -17.6400 8 C1x C 20.7900 -18.3400 9 C1x C 22.0500 -17.6400 10 O2x O 22.0500 -16.2400 11 C1x C 20.7900 -15.5400 12 C1x C 19.6000 -16.2400 13 X F 17.1500 -16.2400 14 N1y N 14.7000 -20.4400 15 C1x C 13.3826 -19.9663 16 C1y C 12.5634 -21.0931 17 O7x O 13.3514 -22.2462 18 C7x C 14.6895 -21.8347 19 O6a O 15.7753 -22.7458 20 C1b C 11.1300 -21.0728 21 N1b N 10.4461 -19.8484 22 C5a C 9.0310 -19.8980 23 C1a C 8.2805 -18.6975 24 O5a O 8.3810 -21.1205 BOND 26 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 2 7 1 8 7 8 1 9 8 9 1 10 9 10 1 11 10 11 1 12 11 12 1 13 7 12 1 14 3 13 1 15 5 14 1 16 14 15 1 17 15 16 1 18 16 17 1 19 17 18 1 20 14 18 1 21 18 19 2 22 16 20 1 #Up 23 20 21 1 24 21 22 1 25 22 23 1 26 22 24 2 |